TMEM61

Across TCGA pan-cancer cohorts, TMEM61 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TMEM61 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TMEM61 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM61 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, HNSC, and ESCA are the cancer types where TMEM61 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.688	<.001	48	view →
HNSC	DFS	Median	All	0.122	0.710	.001	33	view →
ESCA	OS	Median	All	0.022	0.701	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	II,III,IV	0.176	0.677	.047	3	view →
COAD	OS	Median	All	0.529	0.873	.017	3	view →
SKCM	DFS	Median	All	0.805	0.198	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TMEM61–STAD (OS)

Open the STAD breakdown →